Wellkey Holdings Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Nov 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 4, 2027The maintenance fee for Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components (US 9,095,532) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Composition for preventing or treating liver diseases, containing plant stem cell lines derived from the cambium of Panax ginseng including mountain ginseng or ginseng as active ingredient (US 9,289,457) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Composition for cancer prevention or treatment containing as active ingredient plant stem cell line dervied from cambium of Panax ginseng including wild ginseng or ginseng (US 9,314,492) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Method for preparing extract of genus Panax including wild ginseng or ginseng, or cambial meristematic cells derived from genus panax or extract thereof containing rare ginsenosides in high quantity (US 10,646,528) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,585,923 | Antioxidant, anti-inflammatory or anti-aging composition containing taxus cambium- or procambium-derived cell line as active ingredient In force · USPTO record | In force | USPTO record | |
| US 8,247,230 | Plant stem cell line derived from cambium of herbaceous plant with storage root and method for isolating the same In force · USPTO record | In force | USPTO record | |
| US 9,095,532 | Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components In force · USPTO record | In force | USPTO record | |
| US 8,617,621 | Composition for enhancing immunity containing plant stem cell line derived from cambium of Panax ginseng including wild ginseng or ginseng as an active ingredient In force · USPTO record | In force | USPTO record | |
| US 9,314,492 | Composition for cancer prevention or treatment containing as active ingredient plant stem cell line dervied from cambium of Panax ginseng including wild ginseng or ginseng In force · USPTO record | In force | USPTO record | |
| US 9,415,081 | Composition for preventing or treating AIDS containing plant stem cell line derived from cambium of Panax ginseng including wild ginseng or ginseng as active ingredient In force · USPTO record | In force | USPTO record | |
| US 9,289,457 | Composition for preventing or treating liver diseases, containing plant stem cell lines derived from the cambium of Panax ginseng including mountain ginseng or ginseng as active ingredient In force · USPTO record | In force | USPTO record | |
| US 10,646,528 | Method for preparing extract of genus Panax including wild ginseng or ginseng, or cambial meristematic cells derived from genus panax or extract thereof containing rare ginsenosides in high quantity In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 8: 2 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.